Generic Savings: REMS Obstruction, Not ANDA Backlog, Is Main Hindrance, AAM Says
Association for Accessible Medicines report highlights continuing upward trend of cost savings from generic drugs; trade group argues legislative proposals addressing restricted distribution misuse are key to accelerating savings.
You may also be interested in...
House Energy and Commerce Committee refines FDA Reauthorization Act and adopts a ‘sense of Congress’ resolution on drug pricing, but largely steers clear of other potentially controversial add-ons that could bog down the measure.
Report sponsored by Association for Accessible Medicines in US says drugs with restricted distribution programs had total sales of $22.7bn in 2016; seven drugs had sales topping $1bn.
Commissioner Gottlieb outlines several steps agency is taking – including potentially dropping requirement for shared REMS – to create more competitive generic marketplace.